Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Rhythm Biosciences Ltd has successfully raised $3.5 million through a strong share placement, priced at $0.10 per share, to further develop and commercialize its ColoSTAT® Multiplex colorectal cancer test. The placement attracted significant interest from new institutional and sophisticated investors, reflecting confidence in the company’s innovative cancer diagnostics technology. The funds will support the finalization of the test kit, clinical validation, and expansion of their R&D pipeline.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Boeing (NYSE:BA) Layoffs Expand, Start Hitting Multiple Factories
- Microsoft’s (NASDAQ:MSFT) New Computer is Exclusively a Cloud Machine
- Walmart (NYSE:WMT) Warns About Tariff-Driven Price Hikes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
